



One Health in Mycoplasmas: Antimicrobial Susceptibility and Resistance in Mycoplasmas Infecting Humans, Animals, Plants and Insects

Guest Editor:

Prof. Dr. Owen B. Spiller

1. Medical Microbiology, Division
of Infection and Immunity, Cardiff
University, Cardiff, UK
2. Bacteriology Reference
Department, UK Health Security
Agency, London, UK

Deadline for manuscript
submissions:

closed (1 October 2021)

Message from the Guest Editor

Dear Colleagues,

Mycoplasmas are among the smallest forms of life in nature and exist as commensals or pathogens of organisms across the tree of life. They are associated with disease in premature newborn babies and sexually transmitted disease in adults, infectious respiratory disease in domesticated farm animals (pigs, chickens and cattle), as well as wild game (antelope, camels and flamingos), causing infectious damage to fruit crops of citrus trees, and have even been found in jellyfish. The entire over-arching class of *Mollicutes* to which they belong have no cell wall, scavenge nucleotides from their host and commonly reside within host cells, making them completely resistant to most classes of antibiotics. Therefore, monitoring the evolution and spread of resistance to the remaining effective antibiotics is of international concern. This Special Issue is dedicated to the International Organisation of Mycoplasma in its continued effort to monitor resistance, develop new antibiotic therapies and guidelines, and develop alternatives for treating Mycoplasma infection in the face of diminishing effective antibiotics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)